Trefis Team, Contributor / Forbes: Money
Is A Rise Imminent For Intellia Therapeutics Stock After 30% Fall In A Month? – The stock price of Intellia Therapeutics, a biotechnology company developing treatments using a CRISPR gene-editing system, has seen a significant 31% fall in a month while it is down 34% over the last week. This can be attributed to the U.S. Patents Trademark Office ruling invalidating a key…The stock …
